Overview

  • Product nameNADA (N-Arachidonyldopamine)
  • Description
    Endogenous CB1 / TRPV1 agonist
  • Alternative names
    • N-Arachidonyldopamine
  • Biological descriptionPotent endogenous cannabinoid and vanilloid receptor agonist. (Ki values are 0.25 and 12 μM for CB1 and CB2, respectively). Potent agonist at TRPV1 (VR1) receptors (EC50 = ~50 nM). Active in vivo.
  • Purity> 98%

Properties

    Applications

    Our Abpromise guarantee covers the use of ab120099 in the following tested applications.

    The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

    Application Abreviews Notes
    Functional Studies Use at an assay dependent concentration.

    NADA (N-Arachidonyldopamine) images

    • ab15580 staining Ki67 in SK-N-SH cells treated with NADA (N-Arachidonyldopamine) (ab120099), by ICC/IF. Decrease in Ki67 expression correlates with increased concentration of NADA (N-Arachidonyldopamine), as described in literature.
      The cells were incubated at 37°C for 10 minutes in media containing different concentrations of ab120099 (NADA (N-Arachidonyldopamine)) in ethanol, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab15580 (1 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.

    References for NADA (N-Arachidonyldopamine) (ab120099)

    This product has been referenced in:
    • O'Sullivan SE  et al. Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). Br J Pharmacol 141:803-12 (2004). Read more (PubMed: 14769783) »
    • Huang SM  et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 99:8400-5 (2002). Read more (PubMed: 12060783) »
    • Bisogno T  et al. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 351 Pt 3:817-24 (2000). Read more (PubMed: 11042139) »

    See 0 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab120099.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"